ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024
Diabetes accelerates Alzheimer's disease progression in the first year post mild cognitive impairment diagnosis.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Adverse childhood experiences and subsequent impact on adulthood cognitive impairment: a systematic review and meta-analysis.Frontiers in psychiatry · 2025Pooled it
- Investigation of type 2 diabetes mellitus and mild cognitive impairment: a study based on diffusion tensor imaging analysis along the perivascular space and peak width of skeletonized mean diffusivity.Quantitative imaging in medicine and surgery · 2026Article
- Bridge symptoms connecting depressive, sleep, and cognitive domains in rural older adults with type 2 diabetes: a symptom network approach.BMC geriatrics · 2026Article
- GLP-1 agonists in neurodegeneration: a multimodal biomarker-guided approach.Trends in molecular medicine · 2026Review
- Contributions of the Alzheimer's Disease Neuroimaging Initiative to advancing AD research: a targeted review of recent publications.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Evaluation of Frequency, Severity and Spectrum of Cognitive Impairment and Its Associated Risk Factors in Elderly Individuals with Diabetes in India: A Prospective Observational Cohort Study.Advances in therapy · 2026Observational
- Deep learning-driven MRI segmentation of choroid plexus volume: a novel biomarker for cognitive impairment in type 2 diabetes mellitus.Japanese journal of radiology · 2026Article
- Sensory network dysregulation in type 2 diabetes: Linking olfactory, visual, and cognitive function.Diabetes, obesity & metabolism · 2026Article
- Association of peripheral insulin resistance with cognitive impairment in patients with non-disabling ischemic cerebrovascular events and the mediating role of chronic inflammatory biomarkers.European journal of medical research · 2026Article
- Association between estimated glucose disposal rate and cognitive impairment in elderly patients with type 2 diabetes mellitus: a cross-sectional study.Frontiers in endocrinology · 2026Article
- Prevention of cognitive decline and dementia: Current evidence on lifestyle factors and dietary patterns.EXCLI journal · 2026Review
- Activation of Nrf2 signaling and suppression of oxidative stress-induced neuronal apoptosis: mechanisms for baicalin capsules relieving diabetic encephalopathy.Frontiers in pharmacology · 2026Article
- Distinguishing early from late mild cognitive impairment: a multi-level analysis of regional morphometry and KLS-derived network topology.Frontiers in aging neuroscience · 2026Article
- Advances in the treatment of Alzheimer's disease.Frontiers in pharmacology · 2026Review
- Association of genetic scores related to insulin resistance with neurological outcomes in ancestrally diverse cohorts from the Trans-Omics for Precision Medicine (TOPMed) program.Communications biology · 2025Article
- Association Analysis Between Ischemic Stroke Risk Single Nucleotide Polymorphisms and Alzheimer's Disease.Bioengineering (Basel, Switzerland) · 2025Article
- Association between self-reported multimorbidity and longitudinal brain Aβ deposition in Alzheimer's disease.Nature communications · 2025Article
- Hypertension and diabetes on cognitive impairment: a case-control study in China.Alzheimer's research & therapy · 2025Article
- Spontaneous brain activity in patients with type 2 diabetes: linking serum neuroproteins to cognitive ability.Diabetology & metabolic syndrome · 2025Article
- Trelagliptin Ameliorates Memory Decline in Diabetic Rats through the AMPK/AKT/GSK-3β Pathway in the Cerebral Cortex.ACS omega · 2025Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
backgroundMild cognitive impairment (MCI) heightens Alzheimer's disease (AD) risk, with diabetes mellitus (DM) potentially exacerbating this vulnerability. This study identifies the optimal intervention period and neurobiological targets in MCI to AD progression using the Alzheimer's Disease Neuroimaging Initiative dataset.
methodsAnalysis of 980 MCI patients, categorized by DM status, used propensity score matching and inverse probability treatment weighting to assess rate of conversion from MCI to AD, neuroimaging, and cognitive changes.
resultsDM significantly correlates with cognitive decline and an increased risk of progressing to AD, especially within the first year of MCI follow-up. It adversely affects specific brain structures, notably accelerating nucleus accumbens atrophy, decreasing gray matter volume and sulcal depth. DISCUSSION: Findings suggest the first year after MCI diagnosis as the critical window for intervention. DM accelerates MCI-to-AD progression, targeting specific brain areas, underscoring the need for early therapeutic intervention. HIGHLIGHTS: Diabetes mellitus (DM) accelerates mild cognitive impairment (MCI)-to-Alzheimer's disease (AD) progression within the first year after MCI diagnosis. DM leads to sharper cognitive decline within 12 months of follow-up. There is notable nucleus accumbens atrophy observed in MCI patients with DM. DM causes significant reductions in gray matter volume and sulcal depth. There are stronger correlations between cognitive decline and brain changes due to DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.